Home | Publications | Research (R&D) | Pipeline place holder
place holder place holder

Pipeline


Epigenomics AG Product Pipeline Analysis


Publication Date   August 2008
Publisher   Global Markets Direct
Product Type   Report
Pages   47
ISBN Number   not applicable
Product Code   GMD624
Ask a question about this product?

Price £505.00

approximately: $753 | €602

Summary


This report is an insightful source for data, analysis and strategic insights into a Epigenomics AG's pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

  • Details of development stage by sector and equipment type.
  • Pipeline products grouped by therapy area, development stage and trial phase.
  • Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
  • Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
  • Product updates covering estimated approval dates and estimated launch dates.
  • Descriptions of novel technologies relating to pipeline products of the company.
  • Patents and patent applications covered for the product.
  • News updates on key events relating to the product and its development.

Reasons to buy

  • A single source to fulfill competitor information relating to products in development.
  • Identify pipeline products that are potential competitor to your product lines.

Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.

  • Access clinical trial information to map trial results and plan targeted marketing activities.
  • Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
  • Identification of potential investment opportunities.
  • Build up knowledge base for potential distribution and marketing partners.
  • Helps avoid patent infringement.
  • Timelines from concept to market lets you keep track of market potential build for a new product.

Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

Content


  • 1 List of Tables
    • 1.2 List of Figures
  • 2 Company Snapshot
    • 2.1 Key Information
    • 2.2 Company Overview
    • 2.3 Financial Performance
    • 2.4 Industry Outlook - In Vitro Diagnostics
  • 3 Business Description
    • 3.1 Business Overview
    • 3.2 Major Products and Services
      • 3.2.1 Overview
  • 4 Competitors
  • 5 Key Employees
  • 6 Key Employee Biographies
  • 7 Company Statement
  • 8 Locations And Subsidiaries
    • 8.1 Head Office
    • 8.2 Other Locations & Subsidiaries
  • 9 Recent Developments
    • 9.1 Strategy And Business Planning
      • 9.1.1 Jan 14, 2008: Epigenomics Enters Into Strategic Cross-Licensing Agreement With DxS
      • 9.1.2 Jan 14, 2008: Epigenomics Issues Technology Licenses To OncoMethylome
      • 9.1.3 Sep 26, 2007: Epigenomics Signs Agreement With Abbott
      • 9.1.4 May 09, 2007: Epigenomics Enters R&D Collaboration With Myriad
      • 9.1.5 Apr 12, 2007: Epigenomics Forms Alliance With Clinical Data For DNA Methylation Services
    • 9.2 Financial Announcements
      • 9.2.1 Aug 05, 2008: Epigenomics Reports 1H 2008 Results
      • 9.2.2 May 06, 2008: Epigenomics Reports Q1 2008 Results
      • 9.2.3 Mar 31, 2008: Epigenomics Reports 2007 Results
      • 9.2.4 Mar 13, 2008: Epigenomics To Declare 2007 Results
      • 9.2.5 Oct 31, 2007: Epigenomics Declares Q3 2007 Results
      • 9.2.6 Aug 02, 2007: Epigenomics Declares H1 2007 Results
      • 9.2.7 May 03, 2007: Epigenomics Declares Q1 2007 Results
      • 9.2.8 Mar 30, 2007: Epigenomics Declares 2006 Results
    • 9.3 Research And Development
      • 9.3.1 May 09, 2007: Epigenomics Enters R&D Collaboration With Myriad
    • 9.4 Corporate Communications
      • 9.4.1 Aug 05, 2008: Epigenomics Announces Management Changes
      • 9.4.2 Jan 21, 2008: Epigenomics Appoints New Advisory Board Member
      • 9.4.3 Jan 16, 2008: Epigenomics Appoints New CEO
    • 9.5 Product News
      • 9.5.1 Apr 21, 2008: Epigenomics AG Successfully Validates Optimized Blood-Based Colorectal Cancer Assay In Two Independent Clinical Studies
      • 9.5.2 Apr 14, 2008: Epigenomics AG Presents Data on Novel Prostate Cancer Biomarkers at AACR
      • 9.5.3 Feb 19, 2008: Epigenomics Licenses Septin 9 Colorectal Cancer Biomarker To Quest Diagnostics
    • 9.6 Clinical Trials
      • 9.6.1 Apr 21, 2008: Epigenomics AG Successfully Validates Optimized Blood-Based Colorectal Cancer Assay In Two Independent Clinical Studies
  • 10 Epigenomics AG Pipeline Products
    • 10.1 Epigenomics AG Product Pipeline Analysis
      • 10.1.1 Epigenomics AG Pipeline Products By Equipment Type
      • 10.1.2 Epigenomics AG Pipeline Products By Development Stage
      • 10.1.3 Epigenomics AG Pipeline Products By Therapy Area
      • 10.1.4 Epigenomics AG Pipeline Products By Clinical Trials
      • 10.1.5 Epigenomics AG Pipeline Products By News Summary
    • 10.2 Colorectal cancer screening test
      • 10.2.1 Product Description
      • 10.2.2 Product Status
      • 10.2.3 Clinical Trials
      • 10.2.4 Product Milestone
    • 10.3 Prostate Cancer Screening Test
      • 10.3.1 Product Description
      • 10.3.2 Product Status
      • 10.3.3 Product Milestone
    • 10.4 Lung Cancer Screening Test
      • 10.4.1 Product Description
      • 10.4.2 Product Status
      • 10.4.3 Clinical Trials
      • 10.4.4 Product Milestone
  • 11 Appendix
    • 11.1 Methodology
      • 11.1.1 Coverage
      • 11.1.2 Secondary Research
      • 11.1.3 Primary Research
      • 11.1.4 Expert Panel Validation
    • 11.2 Contact Us
    • 11.3 About Global Markets Direct
    • 11.4 Disclaimer
  • 1 List of Tables
    • Table 1: Epigenomics AG,Key Facts
    • Table 2: Epigenomics AG, Key Employees,
    • Table 3: Epigenomics AG, Other Locations
    • Table 4: Epigenomics AG, Subsidiaries
    • Table 5: Epigenomics AG Pipeline Products by Equipment Type
    • Table 6: Epigenomics AG Pipeline Products By Development Stage
    • Table 7: Epigenomics AG Pipeline Products By Therapy Area
    • Table 8: Epigenomics AG Pipeline Products By Clinical Trials
    • Table 9: Epigenomics AG Pipeline Products By News Summaries
    • 1.2 List of Figures
    • Figure 1: Epigenomics AG Pipeline Products By Development Stage
    • Figure 2: Epigenomics AG Pipeline Products By News Summary
    • Figure 3: Global Markets Direct Methodology